A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer
The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.
100 项与 Sopherion Therapeutics LLC 相关的临床结果
0 项与 Sopherion Therapeutics LLC 相关的专利(医药)
100 项与 Sopherion Therapeutics LLC 相关的药物交易
100 项与 Sopherion Therapeutics LLC 相关的转化医学